Deletion or pharmacological inhibition of CK1α is also detrimental to MM cells, indicating that lenalidomide-dependent degradation of CK1α may contribute to its anti-myeloma activity [59,60,61]. The gene discussed is CSNK1A1; the disease is Miyoshi myopathy.